The women’s health market is predicted to be among the fastest growing investment areas within the healthcare and life sciences industry. Life sciences companies and healthcare providers, as well as the governmental bodies that regulate them, are abandoning a “one-size-fits-all” approach to treatment in favor of approaches more tailored to specific groups, including women. King & Spalding’s Women’s Health team has decades of experience advising companies in this space on issues that arise throughout the lifecycle of medical products – including intellectual property issues, corporate and M&A issues, FDA-related issues, issues related to product coverage and reimbursement, healthcare provider issues, and product liability issues. Clients include drug and device manufacturers, health care providers, private equity firms, and others.
Back to Focus on Women's Health
March 14, 2022
Health Headlines– March 14, 2022
February 7, 2022
A Pandemic Silver Lining: FDA’s New Guidance on Using Digital Health Technologies for Clinical Investigations
January 26, 2022
Spotlight on PFAS and Other Substances in Cosmetics Likely to Grow in 2022
March 1, 2022
Melvin Bailey Inducted Into American College of Trial Lawyers
January 26, 2021
Top Healthcare Partner Richard Zall Joins King & Spalding in New York
February 5, 2020
Morty Dubin counsels Johnson & Johnson with its talc trial in New Jersey
King & Spalding Advised the Founder, CEO and Majority Owner of Vogue International in Its $3.3 Billion Sale to Johnson & Johnson Consumer Inc.
Navigating the Future: Considerations Related to “Femtech” and Other Digital Health Tools